Spots Global Cancer Trial Database for human mammary carcinoma
Every month we try and update this database with for human mammary carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | NCT05364450 | Breast Neoplasm Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear | Enhanced Usual ... Acceptance Comm... Cognitive Behav... | 18 Years - 99 Years | Indiana University | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer | NCT01271738 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Human Mammary C... Neoplasms, Brea... | Remove tumor on... Removal of tumo... | 18 Years - | Emory University | |
| Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | NCT05364450 | Breast Neoplasm Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear | Enhanced Usual ... Acceptance Comm... Cognitive Behav... | 18 Years - 99 Years | Indiana University | |
| A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | NCT00091442 | Breast Cancer | Docetaxel DOXIL | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | NCT00426530 | Breast Neoplasm... Neoplasm Metast... | everolimus (RAD... | 18 Years - | Novartis | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | NCT05364450 | Breast Neoplasm Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear | Enhanced Usual ... Acceptance Comm... Cognitive Behav... | 18 Years - 99 Years | Indiana University | |
| A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer | NCT00558545 | Human Mammary C... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | NCT00426556 | Metastatic Brea... | Everolimus Trastuzumab Paclitaxel | 18 Years - | Novartis | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer | NCT01271738 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Human Mammary C... Neoplasms, Brea... | Remove tumor on... Removal of tumo... | 18 Years - | Emory University | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi | |
| Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors | NCT02611544 | Breast Neoplasm... Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear Neoplasm Remiss... Spontaneous Neo... Regression, Spo... Remission, Spon... Spontaneous Neo... | Acceptance and ... Survivorship Ed... Enhanced Usual ... | 18 Years - 99 Years | Indiana University | |
| A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | NCT00091442 | Breast Cancer | Docetaxel DOXIL | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors | NCT02611544 | Breast Neoplasm... Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear Neoplasm Remiss... Spontaneous Neo... Regression, Spo... Remission, Spon... Spontaneous Neo... | Acceptance and ... Survivorship Ed... Enhanced Usual ... | 18 Years - 99 Years | Indiana University | |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | NCT01042925 | Breast Cancer Breast Neoplasm... | XL147 (SAR24540... trastuzumab paclitaxel | 18 Years - | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
